Related Results

Four strengths of doxazosin approvedTeva, Apotex gain approval for doxazosinDoxazosin helps fight metabolic syndromeIvax receives tentative approval for doxazosin mesylate tabletsFinasteride and doxazosin combo halts BPH progress in 67%

COPYRIGHT 2004 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Related Results

Four strengths of doxazosin approvedTeva, Apotex gain approval for doxazosinDoxazosin helps fight metabolic syndromeIvax receives tentative approval for doxazosin mesylate tabletsFinasteride and doxazosin combo halts BPH progress in 67%

COPYRIGHT 2000 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Related Results

Four strengths of doxazosin approvedTeva, Apotex gain approval for doxazosinDoxazosin helps fight metabolic syndromeIvax receives tentative approval for doxazosin mesylate tabletsFinasteride and doxazosin combo halts BPH progress in 67%

COPYRIGHT 2004 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Related Results

Four strengths of doxazosin approvedTeva, Apotex gain approval for doxazosinIvax receives tentative approval for doxazosin mesylate tabletsFinasteride and doxazosin combo halts BPH progress in 67%Doxazosin Not First-line Drug for Hypertension

He reported on 160 hypertensive British ethnic Asian Indians in a double blind, 36-week clinical trial at 17 primary care centers in the United Kingdom. They were randomized to antihypertensive therapy with the alpha-1 receptor blocker doxazosin or bendroflumethiazide.
At 21 weeks and 34 weeks, patients on doxazosin had significant reductions in total cholesterol, triglycerides, and serum glucose levels following a standard 2-hour oral glucose tolerance test compared with baseline. The bendroflumethiazide group had increases in total cholesterol, triglycerides, and serum glucose at both time points.
Fasting insulin was significantly lower at 21 and 34 weeks in the doxazosin group than in bendroflumethiazide group. Levels of nonesterified fatty acid particles were significantly lower at 30 minutes and at 2 hours in patients on doxazosin compared with bendroflumethiazide-treated patients at 21 weeks but not at 34 weeks.
Both agents lowered blood pressure to a comparable degree. Amlodipine was required to reach the target diastolic blood pressure of less than 90 mm Hg in 15.4% of the doxazosin group and 22% of patients in the bendroflumethiazide group.
COPYRIGHT 2005 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning

2006
RANK DRUG DOLLAR SALES

1 Hydrocodone/APAP $1,622,889,152
2 Simvastatin 1,390,478,902
3 Azithromycin 1,216,982,213
4 Oxycodone 1,179,858,560
5 Gabapentin 1,004,639,425

6 Amoxicillin/pot. clav. 926,015,426
7 Fexofenadine 905,379,076
8 Fentanyl transdermal 840,241,732
9 Lisinopril 727,295,602
10 Sertraline 699,973,704

11 Metformin 670,167,205
12 Omeprazole 642,234,889
13 Clopidogrel 634,646,938
14 Paroxetine 621,808,826
15 Fluticasone nasal 616,191,225

16 Amoxicillin 492,911,196
17 Albuterol aerosol 485,365,957
18 Oxycodone w/APAP 483,603,509
19 Levothyroxine 471,734,902
20 Lovastatin 457,336,196

21 Fluoxetine 439,819,467
22 Pravastatin 429,216,916
23 Alprazolam 426,530,871
24 NovoLog 399,904,307
25 Lorazepam 363,573,228

26 Warfarin 340,967,415
27 Atenolol 327,472,550
28 Tramadol 312,997,786
29 Bupropion SR 305,140,442
30 Hydrochlorothiazide 303,123,706

31 Cephalexin 301,682,277
32 Morphine sulfate noninjection 272,585,724
33 Clonazepam 268,035,849
34 Propoxyphene-N/APAP 260,336,005
35 Lisinopril/HCTZ 248,479,020

36 Prednisone oral 238,852,250
37 Quinapril 238,536,662
38 Diltiazem CD 234,826,198
39 Cyclobenzaprine 229,225,760
40 Potassium chloride 227,156,143

41 Nabumetone 223,855,052
42 Furosemide oral 220,438,385
43 Ciprofloxacin HCl 219,779,665
44 Glybrid/metformin HCl 218,736,185
45 Citalopram HBR 217,156,516

46 Minocycline 210,308,763
47 Carisoprodol 207,441,342
48 Nifedipine ER 206,086,828
49 Tramadol HCl/APAP 206,083,171
50 Clindamycin systemic 203,850,665

51 Triamterene w/HCTZ 202,345,414
52 Metoprolol tartrate 195,033,095
53 Amphetamine salt comb. 194,381,833
54 Enalapril 192,255,637
55 Verapamil SR 185,361,133

56 Ibuprofen 182,898,330
57 Cartia XT 181,209,391
58 Glipizide ER 168,179,552
59 Acetaminophen w/codeine 160,303,771
60 Metformin HCl ER 159,688,571

61 Albuterol nebulizer solution 152,123,554
62 Naproxen 148,948,157
63 Spironolactone 146,954,888
64 Mirtazapine 146,469,131
65 Fluconazole 146,036,641

66 Diclofenac sodium 143,683,965
67 Glyburide 143,441,515
68 Ranitidine HCl 141,775,453
69 Hydroxyzine 141,081,382
70 Felodipine ER 135,050,716

71 Trazodone HCl 134,273,554
72 Tizanidine HCl 133,548,518
73 Isosorbide mononitrate 130,623,668
74 Buspirone HCl 128,372,467
75 Promethazine tablets 127,353,408

76 Doxycycline 124,917,827
77 Glimepiride 121,979,761
78 Gemfibrozil 121,684,173
79 Trimethoprim/sulfate 121,201,078
80 Cefprozil 120,515,346

81 Diazepam 117,972,366
82 Nifedical XL 117,479,361
83 Clarithromycin 115,612,170
84 Nitrofurantoin monohydrate micro. 114,679,435
85 Clotrimazol/betamethasone 110,644,415

86 Phentermine 108,201,624
87 Phenytoin sodium extended 107,276,975
88 Etodolac 107,127,913
89 Clonidine 104,947,003
90 Methotrexate 101,927,327

91 Cefuroxime axetil 100,072,635
92 Amitriptyline 98,776,214
93 Methylprednis tablets 98,272,172
94 Carbidopa/levodopa 98,128,354
95 Hydrocodone/ibuprofen 97,374,788

96 Benazepril 97,232,797
97 Mupirocin 95,045,251
98 Nystatin systemic 93,327,096
99 Meloxicam 92,490,846
100 Bupropion ER 91,616,360

101 Penicillin VK 89,231,203
102 Baclofen 87,521,181
103 Fosinopril sodium 85,894,607
104 Benzonatate 85,597,777
105 Acyclovir 85,595,190

106 Nifedipine 84,715,067
107 Clobetasol 84,618,208
108 Allopurinol 84,514,704
109 Amiodarone 82,707,195
110 Quinine sulfate 80,376,319

111 Temazepam 79,306,664
112 Hydroxychloroquine 76,765,413
113 Polyethylene glycol 75,746,671
114 Terazosin 75,085,371
115 Cilostazol 74,961,365

116 Doxazosin 74,539,179
117 Ketoconazole topical 73,145,190
118 Butalbital/APAP/caffeine 72,449,670
119 Bisoprolol/HCTZ 72,336,674
120 Lithium carbonate 69,360,460

121 Clindamycin topical 68,411,316
122 Tamoxifen 67,274,901
123 Nitroglycerin 66,795,922
124 Sotalol 66,597,179
125 Nitrofurantoin mcroc. 65,569,017

126 Labetalol 64,791,744
127 Folic acid 64,356,913
128 Mometasone topical 63,268,756
129 Triamcinln acetone topical 62,816,455
130 Torsemide 62,784,457

131 Metoclopramide 60,939,405
132 Prednisolone sodium phosphate oral 59,408,476
133 Glipizide 59,130,664
134 Diltiazem 59,027,237
135 Hydralazine 58,241,499

136 Estradiol oral 57,491,430
137 Metronidazole tablets 54,447,203
138 Famotidine 54,287,833
139 Cefadroxil 53,975,687
140 Diltiazem SR 52,990,953

141 Methadone HCl noninjection 52,086,075
142 Methylphenidate 52,027,125
143 Methocarbamol 50,106,016
144 Metolazone 49,318,797
145 Promethazine/codeine 48,351,832

146 Terconazole 45,029,520
147 Propranolol HCl 44,715,780
148 Carbamazepine 40,834,153
149 Hyoscyamine 40,536,597
150 Timolol maleate GFS 40,455,430

151 Fluocinonide 40,181,921
152 Microgestin Fe 1/20 39,218,391
153 Imipramine HCl 37,792,871
154 Nadolol 37,647,030
155 Naproxen sodium 37,208,424

156 Oxybutynin chloride 36,669,584
157 Atenolol chlorthalidone 36,249,763
158 Meclizine HCl 36,168,038
159 Nortriptyline 33,756,771
160 Methadose 33,545,813

161 Sulfamethoxazole/tri. 33,272,276
162 Dicyclomine HCl 31,772,711
163 Benazepril/HCTZ 31,655,117
164 Chlorhexidine gluconate 31,106,489
165 Digoxin 29,756,843

166 Hydrocortisone topical Rx 29,506,605
167 Indomethacin 28,353,203
168 Prochlorperaz mal. 27,307,570
169 Colchicine 26,969,077
170 Prednisolone acet. oph. 26,396,720

171 Bumetanide noninjection 25,904,888
172 Phenobarbital 25,329,933
173 Phenazopyridine HCl 23,978,142
174 Hydroxyzine pamoate 23,539,153
175 Nitroquick 23,448,937

176 Doxepin 22,380,467
177 Medroxyprogesterone tablets 22,299,513
178 Dexamethasone oral 21,902,695
179 Nystatin topical 21,768,533
180 Benztropine 21,642,099

181 Captopril 21,528,366
182 Diphenoxylatec w/ atropine 21,329,194
183 Piroxicam 19,720,490
184 Ferrous sulfate 18,948,688
185 Tetracycline 18,892,932

186 Polymyxin B/trimeth. 18,577,312
187 Ibuprofen liquid 17,321,763
188 Timolol maleate oph. 17,159,304
189 Prednisone intensol 15,408,842
190 Penicillin V potassium 15,094,952

191 Hycocleartussin 14,907,134
192 Indapamide 14,614,116
193 Multivitamin chewables w/fl. 14,475,266
194 Cheratussin AC 14,110,748
195 Promethazine DM 13,990,401

196 Nystatin/triamcinoln 13,368,441
197 Erythromycin ophth. 13,324,332
198 Sodium fluoride 11,716,710
199 Aspirin, enteric-coated 9,976,955
200 Docusate sodium 8,456,144

Source: Verispan, Vector One.

COPYRIGHT 2007 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

However, in only a small number of cases (about 10%) will this hyperplasia be symptomatic and severe enough to require any surgical or medical therapy. The mechanism for hyperplasia may be related to an accumulation of dihydrotestosterone in the prostate, which then binds to nuclear hormone receptors which then trigger the growth. The normal prostate weighs 20 to 30 gm, but most prostates with nodular hyperplasia can weigh as much as 50 to 100 gm. And nodular hyperplasia is NOT a precursor to cancer. A mildly increased PSA (4 to 10 ng/mL) in a patient with a very large prostate can be due to either nodular hyperplasia, or to prostatitis, rather than cancer.

It’s good to know that BPH (enlarged prostate) is a non-cancerous enlargement of the prostate that is very common in men as they age. The inner part of the prostate around the urethra may continue to grow. While this can cause problems with urinating because it can press on the urethra (the tube that carries the urine), BPH is not cancer.

The class of drugs usually used to conventionally treat BPH are the alpha 1-adrenoreceptors, including prazosin, alfuzosin, indoramin, terazosin, doxazosin, and tamsulosin.

Both BPH and prostate cancer, however, can cause similar problems in older men. The “free PSA test” may help determine the difference between BPH and prostate cancer. Prostatitis, BPH, prostate cancer and metastasis are all very common prostate ailments. Many of these symptoms, however, can also be caused by other conditions, such as a urinary tract infection (UTI), acute prostatitis, or even a sexually transmitted disease.

Doctors must determine if a patient’s symptoms are due to prostate cancer, BPH, or to a number of other non-cancer-related conditions. Your doctor conducts a digital rectal exam in order to diagnose BPH. Treatment choices for BPH also include an ever watchful waiting.

Also regular checkups are important even for men who have had surgery for BPH. Learn all you can about the treatment options for these prostate disorders if you’re having prostate symptoms that are keeping you up at night or keeping you up at night with worry. To understand your symptoms more take one of the free self tests for symptoms that are found online.

However, with so many treatment choices now available, men with BPH or prostate cancer sometimes have difficulty deciding on which is the right treatment, and the long-term lifestyle effects that each of the prostate disease treatments may cause, especially if conventional or standard treatment is chosen where there is more risk. Other ways to relieve the symptoms of BPH use radiowaves, microwaves, or electrical current.

Also there is always the natural approach to consider. A natural prostate diet may be an alternative chosen by some men rather than risk chemo drugs or radiation. Many men live well into a much older age with various prostate conditions and suffer no ill consequences. Prostate cancer, an enlarged prostate and BPH used to be diseases of old age but not anymore.

Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid
Public Speaking: 7 Secrets Of Great Public Speakers
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking

Your new patient is a 57-year-old African American man. His blood pressure is 150/95 mm Hg, fasting glucose 115 mg/dL, body mass index 32, and triglycerides 155 mg/dL; he is on no prior medications. During the course of his care you diagnose hypertension with metabolic syndrome and decide to recommend an antihypertensive. Thiazidetype diuretics are your standard initial therapy, but this patient has metabolic syndrome, and you know that certain antihypertensive agents have a more favorable metabolic profile than thiazide diuretics. Furthermore, metabolic differences among races have been touted as reason to use other agents in black patients. Should you recommend a thiazide diuretic, or another agent?
Until now, we’ve had no simple approach to treating hypertension in patients with metabolic syndrome–and half or more of our hypertensive patients over the age of 55 have this disorder.
Now, however, we can base decisions on clinical outcomes data from a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (1) This new subgroup analysis supports use of thiazide-type diuretics in these patients–particularly in black patients–despite the more favorable metabolic profile of calcium channel blockers, alpha-blockers, and angiotensin-converting enzyme (ACE) inhibitors.
Cost is no longer as big a factor as it once was, now that ACE inhibitors and alpha-blockers, as well as thiazide diuretics, are available generically.
* Does a better metabolic profile improve outcomes?
We have had reason to be concerned about the metabolic adverse effects of thiazide-type diuretics in the past. Studies published before this ALLHAT subgroup analysis showed that hydrochlorothiazide for essential hypertension had adverse effects on potassium, glucose, and lipid metabolism. Some speculated that these changes aggravate the metabolic changes in early diabetes (2-4) and may contribute to increased coronary heart disease risk. (5,6)
ACE inhibitors and ARBs
The metabolic benefits of ACE inhibitors and angiotensin-receptor blockers (ARBs) are widely known. In comparative studies prior to this ALLHAT subgroup analysis, ACE inhibitors were thought to be preferable to thiazide diuretics and beta-blockers for patients with obesity (7) or the metabolic syndrome. (8) These agents also protect against diabetic nephropathy. (9) Other studies attribute additional vascular benefits to ACE inhibitors, (10) beyond that of lowering blood pressure.
A 2005 meta-analysis by Abuissa et al (11) showed that ACE inhibitors and ARBs were associated with significant reductions in the incidence of newly diagnosed diabetes, which, in turn, might lead to reduced heart disease. That report concluded that use of ACE inhibitors or ARBs should be considered in patients with prediabetic conditions such as metabolic syndrome, hypertension, impaired fasting glucose, family history of diabetes, obesity, congestive heart failure, or coronary heart disease.
Calcium-channel blockers and alpha-blockers
Calcium-channel blockers and alpha-blockers also do not appear to have the adverse metabolic effects of thiazides, and have also been advocated over beta-blockers and thiazides for hypertensive patients with metabolic syndrome. (12-15)
Racial differences
In a consensus statement developed before the findings from the ALLHAT subgroup analysis were available, it was noted that racial differences in metabolic syndrome may make the selection of antihypertensive agents particularly important in African American patients. (16)
* ALLHAT and JNC7 recommendations
The 2002 ALLHAT demonstrated that chlorthalidone (a thiazide-type diuretic) is superior to lisinopril, amlodipine, and doxazosin in preventing 1 or more major forms of cardiovascular disease. No difference was observed, however, for fatal coronary heart disease, nonfatal myocardial infarction, or all-cause mortality. (17) These findings persisted in subgroup analyses stratified by race, diabetic status, and level of renal function, but ALLHAT did not identify patients with metabolic syndrome a priori.
The ALLHAT influenced the 2003 Joint National Commission VII (JNC7) Report, which recommends thiazide diuretics for first-line treatment of hypertension in the absence of compelling indications to begin an alternative antihypertensive agent. (18)
Special consideration, but no recommendation. The JNC7 Report mentions the metabolic syndrome as a special consideration, but does not explicitly recommend a first-line therapy other than thiazides.

Prostate cancer is a disease in which the cells of the prostate become abnormal. They start to grow uncontrollably, forming tumors. A tumor is a mass or lump of tissue made of abnormal cells. Tumors may be malignant or benign. A malignant tumor can spread to other parts of the body. Malignant tumors are cancerous. Benign tumors cannot spread to other parts of the body.

Causes

Increasing age and the presence of normal male hormones (testosterone and dihydrotestosterone [DHT]) are the best-known factors that contribute to BPH. A hormone known as 5?-reductase converts testosterone into DHT in the prostate gland, which results in prostate enlargement. DHT concentrations in BPH tissue have been shown to be increased when compared with normal prostate tissue.

The actual cause of prostate enlargement is unknown. It is believed that factors linked to aging and the testicles themselves may play a role in the growth of the gland. Men who have had their testicles removed at a young age (for example, as a result of testicular cancer) do not develop BPH.

For some men, it suddenly becomes impossible to urinate (known as acute retention). Studies have shown that acute retention affects between 1 and 2 per cent of men with BPH each year. This condition is very painful and demands immediate medical treatment to avoid damage to the kidneys, among other things.

Treatment

The surgeon (urologist) must first prove that the prostatic enlargement is the cause of the symptoms. He may find it helpful to measure the urinary flow rate. This is a simple test: you pass urine into a large funnel and the time taken for a particular volume of urine to pass is calculated electronically. The urologist will also arrange an x-ray or ultrasound scan to make a picture of the bladder after an attempt at emptying. This will reveal whether the prostate is causing obstruction to the urethra. The ultrasound scan will also check that the kidneys are normal. In some hospitals, the size and the shape of the prostate can also be measured by ultrasound.

Medications

Alpha blockers. These drugs were originally developed to treat high blood pressure. They relax muscles around your bladder neck and make it easier to urinate. Four alpha blockers have been approved by the Food and Drug Administration (FDA) for treatment of BPH: terazosin (Hytrin), doxazosin (Cardura), tamsulosin (Flomax) and alfuzosin (Uroxatral).

Remedies

Pumpkin seeds are an effective home remedy for prostate problems and many patients have been helped by their use. These seeds are rich in unsaturated fatty acids which are essential to the health of the prostate. Persons beyond the age of fifty, who have any signs of prostate trouble; or those who suffer from urinary disorders of some kind, namely, burning or difficulty in passing urine freely, should take sixty to ninety grams of pumpkin steeds per day.